AGA1
MCID: ALP061
MIFTS: 51

Alopecia, Androgenetic, 1 (AGA1)

Categories: Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Alopecia, Androgenetic, 1

MalaCards integrated aliases for Alopecia, Androgenetic, 1:

Name: Alopecia, Androgenetic, 1 57 5 36 71
Androgenetic Alopecia 57 19 42 16 71 75
Androgenic Alopecia 19 42
Female Pattern Baldness 42
Female Pattern Alopecia 71
Alopecia, Androgenetic 12
Male Pattern Alopecia 42
Male Pattern Baldness 42
Alopecia Androgenetic 53
Pattern Baldness 42
Aga1 57
Aga 57

Characteristics:


Inheritance:

Autosomal dominant in males 57

Classifications:



External Ids:

OMIM® 57 109200
OMIM Phenotypic Series 57 PS203655
MedGen 40 C4049090
SNOMED-CT via HPO 69 278040002 56317004
UMLS 71 C0162311 C0263477 C4049090

Summaries for Alopecia, Androgenetic, 1

MedlinePlus Genetics: 42 Androgenetic alopecia is a common form of hair loss in both men and women. In men, this condition is also known as male-pattern baldness. Hair is lost in a well-defined pattern, beginning above both temples. Over time, the hairline recedes to form a characteristic "M" shape. Hair also thins at the crown (near the top of the head), often progressing to partial or complete baldness.The pattern of hair loss in women differs from male-pattern baldness. In women, the hair becomes thinner all over the head, and the hairline does not recede. Androgenetic alopecia in women rarely leads to total baldness.Androgenetic alopecia in men has been associated with several other medical conditions including coronary heart disease and enlargement of the prostate. Additionally, prostate cancer, disorders of insulin resistance (such as diabetes and obesity), and high blood pressure (hypertension) have been related to androgenetic alopecia. In women, this form of hair loss is associated with an increased risk of polycystic ovary syndrome (PCOS). PCOS is characterized by a hormonal imbalance that can lead to irregular menstruation, acne, excess hair elsewhere on the body (hirsutism), and weight gain.

MalaCards based summary: Alopecia, Androgenetic, 1, also known as androgenetic alopecia, is related to alopecia and androgenic alopecia. An important gene associated with Alopecia, Androgenetic, 1 is AFA1 (Alopecia, Androgenetic), and among its related pathways/superpathways are Metabolism of steroids and Transcription Androgen Receptor nuclear signaling. The drugs Acetylcysteine and Cysteine have been mentioned in the context of this disorder. Affiliated tissues include prostate, ovary and heart, and related phenotype is alopecia.

OMIM®: 57 Androgenetic alopecia is characterized by a loss of hair from the scalp that follows a defined pattern (Hamilton, 1951). It occurs in women as well as in men. It is caused by a shortening of the anagen (growth) phase and miniaturization of the hair follicle, which results in the formation of progressively thinner, shorter hair (Bergfeld, 1995). In men, the condition is often referred to as male pattern baldness (MPB) and appears to be androgen-dependent (Hamilton, 1942). The condition is hereditary, and follows a pattern that may be consistent with an autosomal dominant trait (Osborn, 1916). Linkage evidence for an autosomal locus on 3q26 (AGA1) has been identified (Hillmer et al., 2008). See 300710 (AGA2) for a discussion of X linkage of androgenetic alopecia. A third locus has been found on chromosome 20p11 (AGA3; 612421). (109200) (Updated 08-Dec-2022)

GARD: 19 Androgenetic alopecia is a common form of hair loss in both men and women. In men, hair is usually lost in a well-defined pattern, beginning above both temples and is usually referred to as male-pattern baldness. Over time, the hairline recedes to form a characteristic 'M' shape. Hair also thins near the top of the head, often progressing to partial or complete baldness. The pattern of hair loss in women differs from men (female pattern hair loss). In women, the hair becomes thinner all over the head, and the hairline does not recede. Androgenetic alopecia in women rarely leads to total baldness. A variety of genetic and environmental factors likely play a role in causing this condition. Genetic changes in the AR gene have also been associated with Androgenetic alopecia.

Related Diseases for Alopecia, Androgenetic, 1

Diseases in the Alopecia, Androgenetic, 1 family:

Alopecia, Androgenetic, 2 Alopecia, Androgenetic, 3

Diseases related to Alopecia, Androgenetic, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 516)
# Related Disease Score Top Affiliating Genes
1 alopecia 31.6 SRD5A2 SRD5A1 SHBG CYP19A1 AR
2 androgenic alopecia 31.6 TGFB2 SRD5A2 SRD5A1 SHBG CYP19A1 AR
3 telogen effluvium 31.0 SRD5A2 SHBG AR
4 impotence 30.8 SRD5A1 SHBG AR
5 prostatic hyperplasia, benign 30.8 SRD5A2 SRD5A1 AR
6 hair disease 30.6 SRD5A2 SHBG AR
7 acne 30.1 SRD5A1 SHBG CYP21A2 CYP19A1 AR
8 prostatic hypertrophy 30.1 SRD5A2 SHBG AR
9 hyperandrogenism 30.1 SRD5A1 SHBG CYP21A2 CYP19A1 AR
10 ovarian cyst 30.0 SHBG CYP19A1
11 polycystic ovary syndrome 29.9 SRD5A1 SHBG CYP21A2 CYP19A1 AR
12 prostate disease 29.9 SRD5A1 CYP19A1 AR
13 hypogonadism 29.9 SHBG CYP19A1 AR
14 gynecomastia 29.8 SRD5A2 SRD5A1 SHBG CYP19A1 AR
15 androgen insensitivity syndrome 29.7 SRD5A2 SRD5A1 SHBG AR
16 male infertility 29.5 SHBG CYP21A2 CYP19A1 AR
17 lipoid congenital adrenal hyperplasia 29.2 SRD5A2 SRD5A1 SHBG CYP21A2 CYP19A1 AR
18 premature menopause 29.0 SRD5A2 SHBG CYP21A2 CYP19A1 AR
19 hypogonadotropic hypogonadism 28.8 STS SRD5A2 SHBG CYP21A2 CYP19A1 AR
20 prostate cancer 28.2 XIAP TGFB2 SRD5A2 SRD5A1 SHBG CYP19A1
21 aspartylglucosaminuria 11.7
22 lysosomal storage disease 11.3
23 glucocorticoid resistance, generalized 11.2
24 hypotrichosis 1 11.1
25 hypotrichosis simplex 11.1
26 fabry disease 11.1
27 tinea favosa 10.9
28 rapidly involuting congenital hemangioma 10.9
29 alopecia areata 10.8
30 abdominal obesity-metabolic syndrome 1 10.6
31 type 2 diabetes mellitus 10.5
32 frontal fibrosing alopecia 10.5
33 covid-19 10.5
34 seborrheic dermatitis 10.5
35 polycystic ovary syndrome 1 10.4
36 hypertrichosis 10.4
37 lipid metabolism disorder 10.3
38 celiac disease 1 10.3
39 skin disease 10.3
40 ichthyosis, x-linked 10.3
41 inflammatory bowel disease 10.3
42 esophagitis 10.3
43 diarrhea 10.3
44 bowel dysfunction 10.3
45 arteries, anomalies of 10.3
46 hair whorl 10.3
47 nephrolithiasis, calcium oxalate 10.3
48 coronary heart disease 1 10.3
49 hyperlipoproteinemia, type iii 10.3
50 lipoprotein quantitative trait locus 10.3

Graphical network of the top 20 diseases related to Alopecia, Androgenetic, 1:



Diseases related to Alopecia, Androgenetic, 1

Symptoms & Phenotypes for Alopecia, Androgenetic, 1

Human phenotypes related to Alopecia, Androgenetic, 1:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 alopecia 30 HP:0001596

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Hair:
early baldness

Clinical features from OMIM®:

109200 (Updated 08-Dec-2022)

Drugs & Therapeutics for Alopecia, Androgenetic, 1

Drugs for Alopecia, Androgenetic, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
2
Cysteine Approved, Nutraceutical Phase 4 52-90-4 594 5862
3 N-monoacetylcystine Phase 4
4
Cetirizine Approved Phase 2, Phase 3 83881-51-0 2678
5
Histamine Approved, Investigational Phase 2, Phase 3 51-45-6 774
6 Pharmaceutical Solutions Phase 3
7 Neurotransmitter Agents Phase 2, Phase 3
8 Anti-Allergic Agents Phase 2, Phase 3
9
Histamine phosphate Phase 2, Phase 3 51-74-1 134614
10 Histamine H1 Antagonists, Non-Sedating Phase 2, Phase 3
11 Histamine H1 Antagonists Phase 2, Phase 3
12 Histamine Antagonists Phase 2, Phase 3
13 Anti-Infective Agents Phase 2, Phase 3
14
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068
15
Zinc cation Approved, Experimental, Investigational Phase 1, Phase 2 7440-66-6, 23713-49-7 32051
16
Bimatoprost Approved, Investigational Phase 2 155206-00-1 5311027
17
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
18
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
19
Dutasteride Approved, Investigational Phase 2 164656-23-9 6918296
20
Dinoprost tromethamine Approved, Vet_approved Phase 1, Phase 2 38562-01-5
21
Dinoprost Approved, Investigational Phase 1, Phase 2 551-11-1 5283078 5280363
22
Ascorbic acid Approved, Nutraceutical Phase 1, Phase 2 50-81-7 54676860 54670067 5785
23
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-16-7, 110-17-8 444266 444972
24 Ammonium trichloro(dioxoethylene-O,O'-)tellurate Phase 2
25 Antiviral Agents Phase 2
26 Radiation-Protective Agents Phase 2
27 Adjuvants, Immunologic Phase 2
28 Reverse Transcriptase Inhibitors Phase 2
29 Immunologic Factors Phase 2
30 Protective Agents Phase 2
31 Trace Elements Phase 1, Phase 2
32 Micronutrients Phase 1, Phase 2
33 Bronchodilator Agents Phase 1, Phase 2
34 Anti-Asthmatic Agents Phase 1, Phase 2
35 Endothelium-Dependent Relaxing Factors Phase 1, Phase 2
36 Respiratory System Agents Phase 1, Phase 2
37 Antioxidants Phase 1, Phase 2
38 Zinc Supplement Phase 1, Phase 2
39 Chelating Agents Phase 1, Phase 2
40 HIV Protease Inhibitors Phase 2
41 Proteasome Inhibitors Phase 2
42
protease inhibitors Phase 2
43 Mitogens Phase 1, Phase 2
44 Androgens Phase 2
45
abobotulinumtoxinA Phase 2
46 Botulinum Toxins, Type A Phase 2
47 Cholinergic Agents Phase 2
48 Ophthalmic Solutions Phase 2
49 Psychotropic Drugs Phase 2
50 Anticonvulsants Phase 2

Interventional clinical trials:

(show top 50) (show all 158)
# Name Status NCT ID Phase Drugs
1 Topical Cetirizine Gel Versus Minoxidil 5% Gel in Treatment of Androgenetic Alopecia Unknown status NCT04293822 Phase 4 Cetirizine;Minoxidil
2 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
3 Efficacy and Tolerability of N-Acetyl- Cysteine for Treatment of The Early-onset Androgenetic Alopecia in Men Unknown status NCT04209803 Phase 4 Minoxidil 5% topically and oral NAC 600 mg
4 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Unknown status NCT03388840 Phase 4
5 Minoxidil in Treatment of Androgenetic Alopecia Completed NCT04090801 Phase 4 Topical minoxidil 5% in 90% ethanol and 5% propylene glycol;Topical minoxidil 5% in pure ethanol alone
6 The Use of Hydradermabrasion in the Scalp to Improve Scalp Health and Improve Outcomes in Androgenetic Alopecia Recruiting NCT05426629 Phase 4
7 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
8 BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA Unknown status NCT01655108 Phase 3 Minoxidil;Saline
9 Evaluating the Efficacy of Topical Herbal Solution on the Treatment of Androgenetic Alopecia and Comparison With Minoxidil 5%: A Double-Blind, Randomized, Clinical Trial Study Completed NCT03753113 Phase 3 Topical Herbal Solution;Topical Minoxidil 5%
10 A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
11 An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
12 Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
13 A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
14 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia Completed NCT03742518 Phase 2, Phase 3 Topical SM04554 solution;Topical vehicle solution
15 Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume Completed NCT00958750 Phase 3 minoxidil
16 Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia: A Randomized, Double-blind Clinical Trial Completed NCT05296863 Phase 3
17 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
18 A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males Completed NCT00151515 Phase 3 minoxidil
19 A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
20 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia) Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
21 A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) Completed NCT04019795 Phase 3
22 Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
23 A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
24 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AD-208 in Male Patients With Androgenetic Alopecia Recruiting NCT04825561 Phase 3 AD-208;AD-2081;placebo of AD-208;placebo of AD-2081
25 The Role of Cetirizine in Androgenetic Alopecia in Females Active, not recruiting NCT04481412 Phase 2, Phase 3 Topical cetirizine;Placebo;Topical minoxidil
26 A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Finasteride Spray (CU-40102) in Chinese Adult Male Patients With Androgenetic Alopecia (AGA) Active, not recruiting NCT05135468 Phase 3 CU-40102 Spray
27 National, Multicentre, Randomized, Double-blind, Double-dummy Phase III Clinical Trial to Evaluate the Efficacy and Safety of Finlândia Hair Lotion Association in the Treatment of Androgenetic Alopecia. Not yet recruiting NCT04594018 Phase 3 Finlândia Association + finasteride placebo;Minoxidil + finasteride
28 A Randomized, Double Blind, Parallel-group Study to Evaluate the Efficacy and Safety of a New Pharmaceutical Form Minoxidil 5% for the Treatment of Androgenetic Alopecia in Men for 24 Weeks Not yet recruiting NCT04721548 Phase 3 Minoxidil Topical Foam;Placebo
29 A Phase 2 Multicenter, Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men Unknown status NCT00471510 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
30 Phase 2 Study of Topical AS101 for the Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women Unknown status NCT00418249 Phase 2 AS101
31 A Multi-center, Randomized, Controlled, Double-blind Study That Evaluates a Low Level Laser Therapy Over-the-counter at Home Device, Theradome™ LH80 PRO vs a Sham Device, for Promoting Hair Growth in Males Diagnosed With Androgenetic Alopecia Unknown status NCT02528552 Phase 2
32 A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic Alopecia (AGA) Unknown status NCT01643629 Phase 1, Phase 2
33 A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate Safety & Efficacy Of Autologous Human Platelet Lysate For Treatment Of Androgenetic Alopecia In Patients Undergoing Hair Transplant Unknown status NCT01644422 Phase 1, Phase 2
34 Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia Unknown status NCT01347957 Phase 1, Phase 2
35 The Clinical Effects of HSC (Hair Stimulating Complex) on Hair Growth in Androgenetic Alopecia: A Phase I/II Clinical Trial Unknown status NCT01501617 Phase 1, Phase 2
36 A Pilot Study of the Efficacy in Treatment of Female Pattern Hair Loss Using 5% Minoxidil Solution Combinded With Oral Chelated Zinc Supplement Unknown status NCT01662089 Phase 1, Phase 2 15 mg Chelate zinc supplement;Placebo drug supplement
37 A Randomized, Double-blind, Vehicle-controlled, Dose-finding Multi-center, Phase 2a Trial of FOL-005 Topical Formulations to Investigate Hair Growth Potential and Safety in Healthy Male Volunteers With Androgenetic Alopecia Completed NCT04774874 Phase 2 Topical formulation
38 A Phase 2 Multicenter, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men Completed NCT00418730 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
39 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males Completed NCT02781311 Phase 2 Setipiprant;Placebo;Finasteride
40 A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Completed NCT02275351 Phase 2 SM04554;Vehicle
41 A Single-center, Active-controlled, Randomized, Double-blind, Proof of Concept Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application in Male Patients With Androgenetic Alopecia Completed NCT02280603 Phase 1, Phase 2 DA-4001C;5% minoxidil
42 A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androgenetic Alopecia (AGA) Completed NCT02279823 Phase 2 CB-03-01 solution;Minoxidil Solution 5%;Placebo solution
43 A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing Completed NCT02503137 Phase 2 Topical SM04554 solution;Topical Vehicle solution
44 A Prospective, Single Center, Open Label, Proof of Principle Study to Assess the Efficacy and Safety of 150 Units of Botulinum Toxin-A Intra-Muscular Injection in the Prevention of Hair Loss in Men With Androgenetic Alopecia Completed NCT00965640 Phase 2 Botulinum Toxin - A injections
45 An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution Completed NCT03495817 Phase 2 ATI-50002
46 Investigator-Initiated, Double Blind, Two-Armed, Placebo-Controlled, Randomized Clinical Trial With an Open-Label Extension Phase, to Investigate Efficacy of 5% Minoxidil Topical Foam Twice Daily in Men With Androgenetic Alopecia in the Temple and Vertex Region Concerning Hair Volume Over 24 / 104 Weeks Completed NCT01319370 Phase 2 Minoxidil;vehicle of 5% Minoxidil topical foam
47 Randomized, Single-centre, Double-blind, Placebo-controlled, Phase I / IIa Study to Evaluate the Safety and Efficacy of Human Autologous Hair Follicle Dermal Sheath Cup Cells (DSCC) in Women and Men With Androgenetic Alopecia. Completed NCT01286649 Phase 1, Phase 2
48 Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia Completed NCT02865421 Phase 2 stem cells;platelet rich plasma
49 Multicenter, Randomised, Open Label, Comparative Clinical Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss (Including AGA Ludwig's Type 1-2) Completed NCT01900041 Phase 2 Pantovigar;Minoxidil 2% only
50 A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of ex Vivo-cultured, Expanded, Occipital Autologous Dermal and Epidermal Cells, Injected Into the Hair Loss Area of the Scalp of Male and Female Subjects With Alopecia Completed NCT01669746 Phase 2

Search NIH Clinical Center for Alopecia, Androgenetic, 1

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Alopecia, Androgenetic, 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Alopecia, Androgenetic, 1:
RepliCel Hair-01 (RCH-01), hair follicle-derived mesenchymal stem cells for treatment of androgenetic alopecia
Embryonic/Adult Cultured Cells Related to Alopecia, Androgenetic, 1:
Hair follicle mesenchymal stem cells (RepliCel Hair-01)

Genetic Tests for Alopecia, Androgenetic, 1

Anatomical Context for Alopecia, Androgenetic, 1

Organs/tissues related to Alopecia, Androgenetic, 1:

MalaCards : Prostate, Ovary, Heart, Skin, Adipocyte, Brain, Breast

Publications for Alopecia, Androgenetic, 1

Articles related to Alopecia, Androgenetic, 1:

(show top 50) (show all 2840)
# Title Authors PMID Year
1
Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. 62 57
18304493 2008
2
The hairless gene in androgenetic alopecia: results of a systematic mutation screening and a family-based association approach. 62 57
11966690 2002
3
Androgenetic alopecia in heterozygous carriers of a mutation in the human hairless gene. 62 57
10827399 2000
4
Genetic analysis of male pattern baldness and the 5alpha-reductase genes. 62 57
9620288 1998
5
Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. 62 57
7849715 1994
6
Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. 62 57
8334753 1993
7
The inheritance of common baldness: two B or not two B? 62 57
6512048 1984
8
Patterned loss of hair in man; types and incidence. 57
14819896 1951
9
Novel anti-prostate cancer curcumin analogues that enhance androgen receptor degradation activity. 53 62
19663790 2009
10
Recent positive selection of a human androgen receptor/ectodysplasin A2 receptor haplotype and its relationship to male pattern baldness. 53 62
19373488 2009
11
Evaluation of androgen receptor gene as a candidate gene in female androgenetic alopecia. 53 62
19538365 2009
12
Androgen receptor copy number variation and androgenetic alopecia: a case-control study. 53 62
19340294 2009
13
Finasteride treatment and neuroactive steroid formation. 53 62
19655698 2009
14
Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old. 53 62
18363752 2008
15
trans-3,4'-Dimethyl-3-hydroxyflavanone, a hair growth enhancing active component, decreases active transforming growth factor beta2 (TGF-beta2) through control of urokinase-type plasminogen activator (uPA) on the surface of keratinocytes. 53 62
18310908 2008
16
Men with Kennedy disease have a reduced risk of androgenetic alopecia. 53 62
17596176 2007
17
Baldness and the androgen receptor: the AR polyglycine repeat polymorphism does not confer susceptibility to androgenetic alopecia. 53 62
17256155 2007
18
[Premature androgenetic alopecia in adult male with nonclassic 21-OH deficiency. A novel nonsense CYP21A2 mutation (Y336X) in 2 affected siblings]. 53 62
17145028 2006
19
A new look at the 5alpha-reductase inhibitor finasteride. 53 62
16834758 2006
20
The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. 53 62
15824176 2005
21
Solubilization and solid-state characterization of a poorly soluble 5-alpha reductase inhibitor. 53 62
15285330 2004
22
Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. 53 62
14729013 2004
23
Testosterone metabolism in human skin cells in vitro and its interaction with estradiol and dutasteride. 53 62
14528059 2003
24
Analysis of genetic polymorphisms of steroid 5alpha-reductase type 1 and 2 genes in Korean men with androgenetic alopecia. 53 62
12670724 2003
25
Male-pattern baldness is common in men with X-linked recessive ichthyosis. 53 62
14571075 2003
26
Acne: effect of hormones on pathogenesis and management. 53 62
12358558 2002
27
Steroid sulfatase in the human hair follicle concentrates in the dermal papilla. 53 62
11886493 2001
28
Production rates of dihydrotestosterone in healthy men and women and in men with male pattern baldness: determination by stable isotope/dilution and mass spectrometry. 53 62
11739436 2001
29
Androgen responsive genes as they affect hair growth. 53 62
11399535 2001
30
The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles. 53 62
11125319 2000
31
[Hormonal profile in men with premature androgenic alopecia]. 53 62
10953626 2000
32
[Treatment of androgenetic alopecia in the man using systemic 5 alpha-reductase inhibition]. 53 62
9879479 1998
33
Delayed telogen replacement in a boy's scalp. 53 62
9873170 1998
34
Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. 53 62
9284093 1997
35
The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. 53 62
8077349 1994
36
5 alpha-reductase inhibitors and prostatic disease. 53 62
7522999 1994
37
Hormonal status in postmenopausal androgenetic alopecia. 53 62
1478763 1992
38
Preparation of topical bimatoprost with enhanced skin infiltration and in vivo hair regrowth efficacy in androgenic alopecia. 62
35040730 2022
39
Female pattern hair loss and polycystic ovarian syndrome: more than just hirsutism. 62
36226726 2022
40
Microneedle mediated transdermal delivery of β-sitosterol loaded nanostructured lipid nanoparticles for androgenic alopecia. 62
36110028 2022
41
Application of lncRNA-miRNA-mRNA ceRNA network analysis in the treatment of androgenic alopecia. 62
36458379 2022
42
Regenerative medicine strategies for hair growth and regeneration: A narrative review of literature. 62
36382136 2022
43
A Comprehensive Review of Microneedling as a Potential Treatment Option for Androgenetic Alopecia. 62
35930041 2022
44
Dendrobium officinale Polysaccharide (DOP) Promotes Hair Regrowth in Testosterone-Induced Bald Mice. 62
36470987 2022
45
Telemedical care of men with androgenetic alopecia demonstrates improved access to care and patient benefit. 62
35841293 2022
46
Insights into male androgenetic alopecia using comparative transcriptome profiling: hypoxia-inducible factor-1 and Wnt/β-catenin signalling pathways. 62
35862273 2022
47
Transcriptomic analysis identifies regulators of the Wnt signalling and hypoxia-inducible factor pathways as possible mediators of androgenetic alopecia. 62
36199226 2022
48
Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics. 62
36460729 2022
49
Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia. 62
35341398 2022
50
Development and inter-laboratory evaluation of the VISAGE Enhanced Tool for Appearance and Ancestry inference from DNA. 62
36182793 2022

Variations for Alopecia, Androgenetic, 1

ClinVar genetic disease variations for Alopecia, Androgenetic, 1:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SMARCD1 NM_003076.5(SMARCD1):c.1051C>T (p.Arg351Cys) SNV Likely Pathogenic
1687715 GRCh37: 12:50484291-50484291
GRCh38: 12:50090508-50090508
2 FOXC1 NM_001453.3(FOXC1):c.1450C>T (p.His484Tyr) SNV Uncertain Significance
1687627 GRCh37: 6:1612130-1612130
GRCh38: 6:1611895-1611895

Expression for Alopecia, Androgenetic, 1

Search GEO for disease gene expression data for Alopecia, Androgenetic, 1.

Pathways for Alopecia, Androgenetic, 1

GO Terms for Alopecia, Androgenetic, 1

Cellular components related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell body fiber GO:0070852 8.92 SRD5A2 SRD5A1

Biological processes related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 male genitalia development GO:0030539 9.87 SRD5A2 SRD5A1
2 uterus development GO:0060065 9.86 TGFB2 CYP19A1
3 male gonad development GO:0008584 9.86 TGFB2 SRD5A2 SRD5A1 AR
4 steroid metabolic process GO:0008202 9.85 SRD5A2 SRD5A1 CYP21A2
5 hypothalamus development GO:0021854 9.84 SRD5A2 SRD5A1
6 cellular response to testosterone stimulus GO:0071394 9.83 SRD5A1 AR
7 androgen biosynthetic process GO:0006702 9.81 SRD5A2 SRD5A1
8 prostate gland growth GO:0060736 9.8 CYP19A1 AR
9 response to follicle-stimulating hormone GO:0032354 9.78 SRD5A2 SRD5A1
10 response to testosterone GO:0033574 9.77 SRD5A2 SRD5A1 CFLAR
11 androgen catabolic process GO:0006710 9.73 CYP19A1 SRD5A1
12 testosterone biosynthetic process GO:0061370 9.71 CYP19A1 SRD5A2
13 steroid catabolic process GO:0006706 9.63 STS SRD5A2
14 positive regulation of integrin biosynthetic process GO:0045726 9.62 TGFB2 AR
15 steroid biosynthetic process GO:0006694 9.56 SRD5A2 SRD5A1 CYP21A2 CYP19A1
16 androgen metabolic process GO:0008209 9.46 SRD5A2 SRD5A1 CYP19A1
17 female genitalia development GO:0030540 9.1 SRD5A2 SRD5A1 CYP19A1

Molecular functions related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 androgen binding GO:0005497 9.62 SHBG AR
2 cholestenone 5-alpha-reductase activity GO:0047751 9.56 SRD5A2 SRD5A1
3 3-oxo-5-alpha-steroid 4-dehydrogenase activity GO:0003865 9.46 SRD5A2 SRD5A1
4 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.4 SRD5A2 SRD5A1
5 steroid dehydrogenase activity GO:0016229 9.37 SRD5A2 SRD5A1
6 amide binding GO:0033218 9.26 SRD5A2 SRD5A1
7 steroid binding GO:0005496 9.1 SHBG CYP21A2 AR

Sources for Alopecia, Androgenetic, 1

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....